{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T22:13:20Z","timestamp":1792448000168,"version":"4.5.0"},"reference-count":169,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T00:00:00Z","timestamp":1736380800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T00:00:00Z","timestamp":1736380800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Deliv. and Transl. Res."],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Glaucoma is an optic neuropathy in which progressive degeneration of retinal ganglion cells and the optic nerve leads to irreversible visual loss. Glaucoma is one of the leading causes of blindness. The pathogenesis of glaucoma is determined by different pathogenetic mechanisms, including increased intraocular pressure, mechanical stress, excitotoxicity, resistance to aqueous drainage and oxidative stress. Topical formulations are often used in glaucoma treatment, whereas surgical measures are used in acute glaucoma cases. For most patients, long-term glaucoma treatments are given. Poor patient compliance and low bioavailability are often associated with topical therapy, which suggests that sustained-release, long-acting drug delivery systems could be beneficial in managing glaucoma. This review summarizes the eye\u2019s physiology, the pathogenesis of glaucoma, current treatments, including both pharmacological and nonpharmacological interventions, and recent advances in long-acting drug delivery systems for the treatment of glaucoma.<\/jats:p>","DOI":"10.1007\/s13346-024-01779-4","type":"journal-article","created":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T15:25:00Z","timestamp":1736436300000},"page":"1907-1934","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Emerging trends in long-acting sustained drug delivery for glaucoma management"],"prefix":"10.1007","volume":"15","author":[{"given":"Yin Ho","family":"So","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepakkumar","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandip","family":"Gite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Sonawane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Waite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahamatullah","family":"Shaikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lalitkumar K.","family":"Vora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7582-2082","authenticated-orcid":false,"given":"Raghu Raj Singh","family":"Thakur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,9]]},"reference":[{"key":"1779_CR1","unstructured":"National Eye Institute, Facts About Glaucoma, National Institutes of Health. 2009."},{"key":"1779_CR2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/psb.1985","volume":"33","author":"S Mamtora","year":"2022","unstructured":"Mamtora S, Leadbetter D, Atan D. Identification and management of glaucoma. Prescriber. 2022;33:17\u201322. https:\/\/doi.org\/10.1002\/psb.1985.","journal-title":"Prescriber"},{"key":"1779_CR3","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.3192","author":"RN Weinreb","year":"2014","unstructured":"Weinreb RN, Aung T, Medeiros FA. The pathophysiology and treatment of glaucoma: a review. JAMA - J Am Med Association. 2014. https:\/\/doi.org\/10.1001\/jama.2014.3192.","journal-title":"JAMA - J Am Med Association"},{"key":"1779_CR4","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1981.03930010635009","author":"HA Quigley","year":"1981","unstructured":"Quigley HA, Addicks EM, Green WR, Maumenee AE. Optic nerve damage in human glaucoma: Ii. The site of Injury and susceptibility to damage. Arch Ophthalmol. 1981. https:\/\/doi.org\/10.1001\/archopht.1981.03930010635009.","journal-title":"Arch Ophthalmol"},{"key":"1779_CR5","unstructured":"Quigley HA, McKinnon SJ, Zack DJ, Pease ME, Kerrigan-Baumrind LA, Kerrigan DF, Mitchell RS. Retrograde axonal transport of BDNF in retinal ganglion cells is blocked by acute IOP elevation in rats. Invest Ophthalmol Vis Sci. 2000;41(11):3460\u20136."},{"key":"1779_CR6","doi-asserted-by":"publisher","first-page":"4903","DOI":"10.1167\/iovs.07-1661","volume":"49","author":"WK Ju","year":"2008","unstructured":"Ju WK, Kim KY, Lindsey JD, Angert M, Duong-Polk KX, Scott RT, Kim JJ, Kukhmazov I, Ellisman MH, Perkins GA, Weinreb RN. Intraocular pressure elevation induces mitochondrial fission and triggers OPA1 release in glaucomatous optic nerve. Invest Ophthalmol Vis Sci. 2008;49:4903\u201311. https:\/\/doi.org\/10.1167\/iovs.07-1661.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1779_CR7","doi-asserted-by":"publisher","unstructured":"Yap T, Donna P, Almonte M, Cordeiro M. Real-Time Imaging of Retinal Ganglion Cell Apoptosis, Cells. 2018. https:\/\/doi.org\/10.3390\/cells7060060","DOI":"10.3390\/cells7060060"},{"key":"1779_CR8","doi-asserted-by":"publisher","first-page":"101066","DOI":"10.1016\/J.PRETEYERES.2022.101066","volume":"90","author":"Z Wang","year":"2022","unstructured":"Wang Z, Wiggs JL, Aung T, Khawaja AP, Khor CC. The genetic basis for adult onset glaucoma: recent advances and future directions. Prog Retin Eye Res. 2022;90:101066. https:\/\/doi.org\/10.1016\/J.PRETEYERES.2022.101066.","journal-title":"Prog Retin Eye Res"},{"key":"1779_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2014.05.013","author":"Y-C Tham","year":"2014","unstructured":"Tham Y-C, Li X, Wong TY, Quigley HA, Aung T, Cheng C-Y. Global prevalence of Glaucoma and projections of Glaucoma burden through 2040. Ophthalmology. 2014. https:\/\/doi.org\/10.1016\/j.ophtha.2014.05.013.","journal-title":"Ophthalmology"},{"key":"1779_CR10","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1167\/tvst.12.10.18","volume":"12","author":"SS Davuluru","year":"2023","unstructured":"Davuluru SS, Jess AT, Bin Kim JS, Yoo K, Nguyen V, Xu BY. Identifying, understanding, and addressing disparities in Glaucoma Care in the United States. Transl Vis Sci Technol. 2023;12:18. https:\/\/doi.org\/10.1167\/tvst.12.10.18.","journal-title":"Transl Vis Sci Technol"},{"key":"1779_CR11","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2015-307223","author":"VV Kapetanakis","year":"2016","unstructured":"Kapetanakis VV, Chan MPY, Foster PJ, Cook DG, Owen CG, Rudnicka AR. Global variations and time trends in the prevalence of primary open angle glaucoma (POAG): a systematic review and meta-analysis. Br J Ophthalmol. 2016. https:\/\/doi.org\/10.1136\/bjophthalmol-2015-307223.","journal-title":"Br J Ophthalmol"},{"key":"1779_CR12","unstructured":"National Collaborating Centre for Acute Care. (2009). Glaucoma: diagnosis and management of chronic open angle glaucoma and ocular hypertension. Appendices A\u2013G. National Institute for Health and Clinical Excellence (NICE). https:\/\/www.leedsformulary.nhs.uk\/docs\/11.Glaucoma%25;20NICE%25;20summary.pdf"},{"key":"1779_CR13","doi-asserted-by":"publisher","DOI":"10.2165\/00002512-199914050-00006","author":"C Lind\u00e9n","year":"1999","unstructured":"Lind\u00e9n C, Alm A. Prostaglandin analogues in the treatment of glaucoma. Drugs Aging. 1999. https:\/\/doi.org\/10.2165\/00002512-199914050-00006.","journal-title":"Drugs Aging"},{"key":"1779_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2003.11.001","author":"JA Kiland","year":"2004","unstructured":"Kiland JA, Gabelt BT, Kaufman PL. Studies on the mechanism of action of timolol and on the effects of suppression and redirection of aqueous flow on outflow facility. Exp Eye Res. 2004. https:\/\/doi.org\/10.1016\/j.exer.2003.11.001.","journal-title":"Exp Eye Res"},{"key":"1779_CR15","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1007\/s12325-017-0593-9","volume":"34","author":"M Fajgenbaum","year":"2017","unstructured":"Fajgenbaum M, Ansari E. Prescribing trends in a Glaucoma Clinic and adherence to EGS guidelines: a Retrospective, non-interventional, single-center UK Study. Adv Ther. 2017;34:2033\u201342. https:\/\/doi.org\/10.1007\/s12325-017-0593-9.","journal-title":"Adv Ther"},{"key":"1779_CR16","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1080\/17425247.2023.2219053","volume":"20","author":"ZK Al-Qaysi","year":"2023","unstructured":"Al-Qaysi ZK, Beadham IG, Schwikkard SL, Bear JC, Al-Kinani AA, Alany RG. Sustained release ocular drug delivery systems for glaucoma therapy. Expert Opin Drug Deliv. 2023;20:905\u201319. https:\/\/doi.org\/10.1080\/17425247.2023.2219053.","journal-title":"Expert Opin Drug Deliv"},{"key":"1779_CR17","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1016\/j.drudis.2019.05.031","volume":"24","author":"Y Cao","year":"2019","unstructured":"Cao Y, Samy KE, Bernards DA, Desai TA. Recent advances in intraocular sustained-release drug delivery devices. Drug Discov Today. 2019;24:1694\u2013700. https:\/\/doi.org\/10.1016\/j.drudis.2019.05.031.","journal-title":"Drug Discov Today"},{"key":"1779_CR18","unstructured":"Perkins E, Davson H. Human eye. Encyclop\u00e6dia Britannica, Inc; 2018."},{"key":"1779_CR19","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2012.0200","author":"K Cholkar","year":"2013","unstructured":"Cholkar K, Patel SP, Vadlapudi AD, Mitra AK. Novel strategies for anterior segment ocular drug delivery. J Ocul Pharmacol Ther. 2013. https:\/\/doi.org\/10.1089\/jop.2012.0200.","journal-title":"J Ocul Pharmacol Ther"},{"key":"1779_CR20","doi-asserted-by":"publisher","unstructured":"Garhart C, Lakshminarayanan V. Anatomy of the Eye, Handbook of Visual Display Technology. 2015:1\u201310. https:\/\/doi.org\/10.1007\/978-3-642-35947-7_4-2","DOI":"10.1007\/978-3-642-35947-7_4-2"},{"key":"1779_CR21","doi-asserted-by":"publisher","DOI":"10.1111\/j.1442-9071.2010.02363.x","author":"CE Willoughby","year":"2010","unstructured":"Willoughby CE, Ponzin D, Ferrari S, Lobo A, Landau K, Omidi Y. Anatomy and physiology of the human eye: effects of mucopolysaccharidoses disease on structure and function - a review. Clin Exp Ophthalmol. 2010. https:\/\/doi.org\/10.1111\/j.1442-9071.2010.02363.x.","journal-title":"Clin Exp Ophthalmol"},{"key":"1779_CR22","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1007\/S13346-021-01043-Z\/TABLES\/3","volume":"12","author":"MF Adrianto","year":"2022","unstructured":"Adrianto MF, Annuryanti F, Wilson CG, Sheshala R, Thakur RRS. In vitro dissolution testing models of ocular implants for posterior segment drug delivery. Drug Deliv Transl Res. 2022;12:1355\u201375. https:\/\/doi.org\/10.1007\/S13346-021-01043-Z\/TABLES\/3.","journal-title":"Drug Deliv Transl Res"},{"key":"1779_CR23","doi-asserted-by":"publisher","DOI":"10.1098\/rsif.2013.0227","author":"KA Kwon","year":"2013","unstructured":"Kwon KA, Shipley RJ, Edirisinghe M, Ezra DG, Rose G, Best SM, Cameron RE. High-speed camera characterization of voluntary eye blinking kinematics. J R Soc Interface. 2013. https:\/\/doi.org\/10.1098\/rsif.2013.0227.","journal-title":"J R Soc Interface"},{"key":"1779_CR24","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-010-9183-3","author":"R Gaudana","year":"2010","unstructured":"Gaudana R, Ananthula HK, Parenky A, Mitra AK. Ocular drug delivery. AAPS J. 2010. https:\/\/doi.org\/10.1208\/s12248-010-9183-3.","journal-title":"AAPS J"},{"key":"1779_CR25","doi-asserted-by":"publisher","unstructured":"Bachu RD, Chowdhury P, Al-Saedi ZHF, Karla PK, Boddu SHS. Ocular drug delivery barriers\u2014role of nanocarriers in the treatment of anterior segment ocular diseases, Pharmaceutics. 2018. https:\/\/doi.org\/10.3390\/pharmaceutics10010028","DOI":"10.3390\/pharmaceutics10010028"},{"key":"1779_CR26","doi-asserted-by":"publisher","DOI":"10.1002\/anie.201911048","author":"Q Zhao","year":"2019","unstructured":"Zhao Q, Zhang S, Wu F, Li D, Zhang X, Chen W, Xing B. Rational design of nanogels for overcoming the biological barriers in various administration routes. Angew Chem Int Ed. 2019. https:\/\/doi.org\/10.1002\/anie.201911048.","journal-title":"Angew Chem Int Ed"},{"key":"1779_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/0039-6257(93)90141-S","author":"A Urtti","year":"1993","unstructured":"Urtti A, Salminen L. Minimizing systemic absorption of topically administered ophthalmic drugs. Surv Ophthalmol. 1993. https:\/\/doi.org\/10.1016\/0039-6257(93)90141-S.","journal-title":"Surv Ophthalmol"},{"key":"1779_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/0169-409X(95)00010-5","author":"K J\u00e4rvinen","year":"1995","unstructured":"J\u00e4rvinen K, J\u00e4rvinen T, Urtti A. Ocular absorption following topical delivery. Adv Drug Deliv Rev. 1995. https:\/\/doi.org\/10.1016\/0169-409X(95)00010-5.","journal-title":"Adv Drug Deliv Rev"},{"key":"1779_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/b978-0-7020-5554-6.00006-x","author":"JV Forrester","year":"2016","unstructured":"Forrester JV, Dick AD, McMenamin PG, Roberts F, Pearlman E. General and ocular pharmacology. Eye. 2016. https:\/\/doi.org\/10.1016\/b978-0-7020-5554-6.00006-x.","journal-title":"Eye"},{"key":"1779_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/0169-409X(95)00012-V","author":"JC Lang","year":"1995","unstructured":"Lang JC. Ocular drug delivery conventional ocular formulations. Adv Drug Deliv Rev. 1995. https:\/\/doi.org\/10.1016\/0169-409X(95)00012-V.","journal-title":"Adv Drug Deliv Rev"},{"key":"1779_CR31","doi-asserted-by":"publisher","DOI":"10.3109\/10611869409015908","author":"G Meseguer","year":"1994","unstructured":"Meseguer G, Gurny R, Buri P. In vivo evaluation of dosage forms: application of gamma scintigraphy to non-enteral routes of administration. J Drug Target. 1994. https:\/\/doi.org\/10.3109\/10611869409015908.","journal-title":"J Drug Target"},{"key":"1779_CR32","doi-asserted-by":"publisher","DOI":"10.3109\/02713688509025145","author":"SD Klyce","year":"1985","unstructured":"Klyce SD, Crosson CE. Transport processes across the rabbit corneal epithelium: a review. Curr Eye Res. 1985. https:\/\/doi.org\/10.3109\/02713688509025145.","journal-title":"Curr Eye Res"},{"key":"1779_CR33","doi-asserted-by":"publisher","DOI":"10.1152\/ajpcell.1987.253.6.c749","author":"B Gumbiner","year":"1987","unstructured":"Gumbiner B. Structure, biochemistry, and assembly of epithelial tight junctions. Am J Physiol Cell Physiol. 1987. https:\/\/doi.org\/10.1152\/ajpcell.1987.253.6.c749.","journal-title":"Am J Physiol Cell Physiol"},{"key":"1779_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2013.15","author":"J Zavala","year":"2013","unstructured":"Zavala J, L\u00f3pez Jaime GR, Rodr\u00edguez Barrientos CA, Valdez-Garcia J. Corneal endothelium: Developmental strategies for regeneration. Eye (Basingstoke). 2013. https:\/\/doi.org\/10.1038\/eye.2013.15.","journal-title":"Eye (Basingstoke)"},{"key":"1779_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2019.101389","author":"R Suri","year":"2020","unstructured":"Suri R, Beg S, Kohli K. Target strategies for drug delivery bypassing ocular barriers. J Drug Deliv Sci Technol. 2020. https:\/\/doi.org\/10.1016\/j.jddst.2019.101389.","journal-title":"J Drug Deliv Sci Technol"},{"key":"1779_CR36","doi-asserted-by":"publisher","unstructured":"Hohenstein-Blaul NVTU, Kunst S, Pfeiffer N, Grus FH. Biomarkers for glaucoma: from the lab to the clinic, in: Eye (Basingstoke). Nat Publishing Group, 2017: pp. 225\u201331. https:\/\/doi.org\/10.1038\/eye.2016.300","DOI":"10.1038\/eye.2016.300"},{"key":"1779_CR37","doi-asserted-by":"publisher","first-page":"4242","DOI":"10.1167\/iovs.11-8902","volume":"53","author":"SC Sacc\u00e0","year":"2012","unstructured":"Sacc\u00e0 SC, Centofanti M, Izzotti A. New proteins as vascular biomarkers in primary open angle glaucomatous aqueous humor. Invest Ophthalmol Vis Sci. 2012;53:4242\u201353. https:\/\/doi.org\/10.1167\/iovs.11-8902.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1779_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(84)34248-8","author":"J Alvarado","year":"1984","unstructured":"Alvarado J, Murphy C, Juster R. Trabecular Meshwork Cellularity in primary open-angle Glaucoma and nonglaucomatous normals. Ophthalmology. 1984. https:\/\/doi.org\/10.1016\/S0161-6420(84)34248-8.","journal-title":"Ophthalmology"},{"key":"1779_CR39","doi-asserted-by":"publisher","unstructured":"Funke S, Perumal N, Beck S, Gabel-Scheurich S, Schmelter C, Teister J, Gerbig C, Gramlich OW, Pfeiffer N, Grus FH. Glaucoma related proteomic alterations in human retina samples. Sci Rep. 2016;6. https:\/\/doi.org\/10.1038\/srep29759.","DOI":"10.1038\/srep29759"},{"key":"1779_CR40","doi-asserted-by":"publisher","unstructured":"Fiedorowicz E, Cie\u015bli\u0144ska A, Kuklo P, Grzybowski A. Protein biomarkers in glaucoma: a review. J Clin Med. 2021;10. https:\/\/doi.org\/10.3390\/jcm10225388.","DOI":"10.3390\/jcm10225388"},{"key":"1779_CR41","doi-asserted-by":"publisher","unstructured":"Cueto AFV, \u00c1lvarez L, Garc\u00eda M, \u00c1lvarez-barrios A, Artime E, Cueto LFV, Coca-Prados M. Gonz\u00e1lez-iglesias, candidate glaucoma biomarkers: from proteins to metabolites, and the pitfalls to clinical applications. Biology (Basel). 2021;10. https:\/\/doi.org\/10.3390\/biology10080763.","DOI":"10.3390\/biology10080763"},{"key":"1779_CR42","doi-asserted-by":"publisher","unstructured":"Auler N, Tonner H, Pfeiffer N, Grus FH. Antibody and protein profiles in glaucoma: screening of biomarkers and identification of signaling pathways. Biology (Basel). 2021;10. https:\/\/doi.org\/10.3390\/biology10121296.","DOI":"10.3390\/biology10121296"},{"key":"1779_CR43","doi-asserted-by":"publisher","unstructured":"European Glaucoma Society Terminology and Guidelines for Glaucoma, 4th Edition - Chap. 3: Treatment principles and options Supported by the EGS Foundation, British Journal of Ophthalmology. 2017. https:\/\/doi.org\/10.1136\/bjophthalmol-2016-EGSguideline.003","DOI":"10.1136\/bjophthalmol-2016-EGSguideline.003"},{"key":"1779_CR44","unstructured":"American Academy of Ophthalmology Glaucoma Panel. Preferred Practice Pattern guidelines. Primary Open-Angle Glaucoma. American Academy of Ophthalmology; 2010."},{"key":"1779_CR45","doi-asserted-by":"publisher","DOI":"10.1111\/ceo.13501","author":"MA Feinstein","year":"2019","unstructured":"Feinstein MA, Lee JH, Amoozgar B, Liu K, Stewart JM, Lazcano-Gomez G, Porco T, Han Y. Comparison between pars plana and anterior endoscopic cyclophotocoagulation for the treatment of glaucoma. Clin Exp Ophthalmol. 2019. https:\/\/doi.org\/10.1111\/ceo.13501.","journal-title":"Clin Exp Ophthalmol"},{"key":"1779_CR46","doi-asserted-by":"publisher","DOI":"10.3390\/vision1040024","author":"R Beardsley","year":"2017","unstructured":"Beardsley R, Law SK, Caprioli J, Coleman AL, Nouri-Mahdavi K, Hubschman JP, Schwartz SD, Giaconi JA. Comparison of outcomes between endoscopic and transcleral cyclophotocoagulation. Vis (Switzerland). 2017. https:\/\/doi.org\/10.3390\/vision1040024.","journal-title":"Vis (Switzerland)"},{"key":"1779_CR47","doi-asserted-by":"publisher","DOI":"10.1097\/IJG.0b013e318218287f","author":"LJ Katz","year":"2012","unstructured":"Katz LJ, Steinmann WC, Kabir A, Molineaux J, Wizov SS, Marcellino G. Selective laser trabeculoplasty versus medical therapy as initial treatment of glaucoma: a prospective, randomized trial. J Glaucoma. 2012. https:\/\/doi.org\/10.1097\/IJG.0b013e318218287f.","journal-title":"J Glaucoma"},{"key":"1779_CR48","doi-asserted-by":"publisher","DOI":"10.1159\/000334776","author":"PT Khaw","year":"2012","unstructured":"Khaw PT, Chiang M, Shah P, Sii F, Lockwood A, Khalili A. Enhanced trabeculectomy - the moorfields safer surgery system. Dev Ophthalmol. 2012. https:\/\/doi.org\/10.1159\/000334776.","journal-title":"Dev Ophthalmol"},{"key":"1779_CR49","doi-asserted-by":"publisher","DOI":"10.5005\/jp-journals-10008-1160","author":"JCF Gaskin","year":"2014","unstructured":"Gaskin JCF, Nguyen DQ, Ang GS, O\u2019Connor J, Crowston JG. Wound healing modulation in glaucoma filtration surgery\u2014 conventional practices and new perspectives: antivascular endothelial growth factor and novel agents (part II). J Curr Glaucoma Pract. 2014. https:\/\/doi.org\/10.5005\/jp-journals-10008-1160.","journal-title":"J Curr Glaucoma Pract"},{"key":"1779_CR50","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2013.5059","author":"E Rulli","year":"2013","unstructured":"Rulli E, Biagioli E, Riva I, Gambirasio G, De Simone I, Floriani I, Quaranta L. Efficacy and Safety of Trabeculectomy vs Nonpenetrating Surgical procedures. JAMA Ophthalmol. 2013. https:\/\/doi.org\/10.1001\/jamaophthalmol.2013.5059.","journal-title":"JAMA Ophthalmol"},{"key":"1779_CR51","doi-asserted-by":"publisher","DOI":"10.17925\/usor.2011.04.02.88","author":"RG Carassa","year":"2011","unstructured":"Carassa RG. Comparing viscocanalostomy with Trabeculectomy. US Ophthalmic Rev. 2011. https:\/\/doi.org\/10.17925\/usor.2011.04.02.88.","journal-title":"US Ophthalmic Rev"},{"key":"1779_CR52","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-018-0842-6","author":"I Riva","year":"2019","unstructured":"Riva I, Brusini P, Oddone F, Michelessi M, Weinreb RN, Quaranta L. Canaloplasty in the treatment of Open-Angle Glaucoma: a review of patient selection and outcomes. Adv Ther. 2019. https:\/\/doi.org\/10.1007\/s12325-018-0842-6.","journal-title":"Adv Ther"},{"key":"1779_CR53","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S80111","author":"A Al Habash","year":"2015","unstructured":"Al Habash A, Aljasim LA, Owaidhah O, Edward DP. A review of the efficacy of mitomycin C in glaucoma filtration surgery. Clin Ophthalmol. 2015. https:\/\/doi.org\/10.2147\/OPTH.S80111.","journal-title":"Clin Ophthalmol"},{"key":"1779_CR54","doi-asserted-by":"publisher","DOI":"10.1007\/s10384-017-0531-z","author":"M Tanito","year":"2017","unstructured":"Tanito M, Ikeda Y, Fujihara E. Effectiveness and safety of combined cataract surgery and microhook ab interno trabeculotomy in Japanese eyes with glaucoma: report of an initial case series. Jpn J Ophthalmol. 2017. https:\/\/doi.org\/10.1007\/s10384-017-0531-z.","journal-title":"Jpn J Ophthalmol"},{"key":"1779_CR55","doi-asserted-by":"publisher","DOI":"10.4103\/0974-9233.148346","author":"ER Craven","year":"2015","unstructured":"Craven ER. Trabecular micro-bypass shunt (iStent\u00ae: basic science, clinical, and future). Middle East Afr J Ophthalmol. 2015. https:\/\/doi.org\/10.4103\/0974-9233.148346.","journal-title":"Middle East Afr J Ophthalmol"},{"key":"1779_CR56","doi-asserted-by":"publisher","DOI":"10.1097\/ICU.0000000000000458","author":"K Vinod","year":"2018","unstructured":"Vinod K. Suprachoroidal shunts. Curr Opin Ophthalmol. 2018. https:\/\/doi.org\/10.1097\/ICU.0000000000000458.","journal-title":"Curr Opin Ophthalmol"},{"key":"1779_CR57","unstructured":"Minckler D, Baerveldt G, Ramirez MA, Mosaed S, Wilson R, Shaarawy T, et al. Clinical results with the Trabectome, a novel surgical device for treatment of open-angle glaucoma. Trans Am Ophthalmol Soc. 2006;104:40\u201350."},{"key":"1779_CR58","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2415-13-24","author":"M T\u00f6teberg-Harms","year":"2013","unstructured":"T\u00f6teberg-Harms M, Hanson JV, Funk J. Cataract surgery combined with excimer laser trabeculotomy to lower intraocular pressure: effectiveness dependent on preoperative IOP. BMC Ophthalmol. 2013. https:\/\/doi.org\/10.1186\/1471-2415-13-24.","journal-title":"BMC Ophthalmol"},{"key":"1779_CR59","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1111\/ceo.14028","volume":"50","author":"R Lim","year":"2022","unstructured":"Lim R. The surgical management of glaucoma: a review. Clin Exp Ophthalmol. 2022;50:213\u201331. https:\/\/doi.org\/10.1111\/ceo.14028.","journal-title":"Clin Exp Ophthalmol"},{"key":"1779_CR60","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.8.18.3237","author":"JT Whitson","year":"2007","unstructured":"Whitson JT. Glaucoma: a review of adjunctive therapy and new management strategies. Expert Opin Pharmacother. 2007. https:\/\/doi.org\/10.1517\/14656566.8.18.3237.","journal-title":"Expert Opin Pharmacother"},{"key":"1779_CR61","doi-asserted-by":"publisher","unstructured":"Winkler NS, Fautsch MP. Effects of prostaglandin analogues on aqueous humor outflow pathways. J Ocul Pharmacol Ther. 2014;30. https:\/\/doi.org\/10.1089\/jop.2013.0179.","DOI":"10.1089\/jop.2013.0179"},{"key":"1779_CR62","doi-asserted-by":"publisher","unstructured":"Zhou L, Zhan W, Wei X. Clinical pharmacology and pharmacogenetics of prostaglandin analogues in glaucoma. Front Pharmacol. 2022;13. https:\/\/doi.org\/10.3389\/fphar.2022.1015338.","DOI":"10.3389\/fphar.2022.1015338"},{"key":"1779_CR63","doi-asserted-by":"publisher","unstructured":"Brandt JD, Beiser JA, Gordon MO, Kass MA. Central corneal thickness and measured IOP response to topical ocular hypotensive medication in the ocular hypertension treatment study. Am J Ophthalmol. 2004;138. https:\/\/doi.org\/10.1016\/j.ajo.2004.07.036.","DOI":"10.1016\/j.ajo.2004.07.036"},{"key":"1779_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcjo.2016.07.013","author":"R Conlon","year":"2017","unstructured":"Conlon R, Saheb H, Ahmed IIK. Glaucoma treatment trends: a review. Can J Ophthalmol. 2017. https:\/\/doi.org\/10.1016\/j.jcjo.2016.07.013.","journal-title":"Can J Ophthalmol"},{"key":"1779_CR65","unstructured":"Cornel S, ristina Mihaela TC, aniela Adriana ID, Mehdi B. D.S. Imone Algerino, novelties in medical treatment of Glaucoma. Rom J Ophthalmol. 2015;59(2):78\u201387."},{"key":"1779_CR66","doi-asserted-by":"publisher","unstructured":"McAuliffe-Curtin D, Buckley C. Review of alpha adrenoceptor function in the eye. Eye (Basingstoke). 1989;3. https:\/\/doi.org\/10.1038\/eye.1989.71.","DOI":"10.1038\/eye.1989.71"},{"key":"1779_CR67","doi-asserted-by":"publisher","unstructured":"Arthur S, Cantor LB. Update on the role of alpha-agonists in glaucoma management. Exp Eye Res. 2011;93. https:\/\/doi.org\/10.1016\/j.exer.2011.04.002.","DOI":"10.1016\/j.exer.2011.04.002"},{"key":"1779_CR68","doi-asserted-by":"publisher","unstructured":"Prum BE, Lim MC, Mansberger SL, Stein JD, Moroi SE, Gedde SJ, Herndon LW, Rosenberg LF, Williams RD. Primary Open-Angle Glaucoma Suspect Preferred Practice Pattern\u00ae Guidelines, Ophthalmology. 2016. https:\/\/doi.org\/10.1016\/j.ophtha.2015.10.055","DOI":"10.1016\/j.ophtha.2015.10.055"},{"key":"1779_CR69","unstructured":"Aslam S, Gupta V. Carbonic anhydrase inhibitors. in: Treasure Island (FL); 2024."},{"key":"1779_CR70","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2467","author":"CT Supuran","year":"2008","unstructured":"Supuran CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov. 2008. https:\/\/doi.org\/10.1038\/nrd2467.","journal-title":"Nat Rev Drug Discov"},{"key":"1779_CR71","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1159\/000348736","volume":"50","author":"P Bettin","year":"2013","unstructured":"Bettin P, Di Matteo F. Glaucoma: Present challenges and future trends. Ophthalmic Res. 2013;50:197\u2013208. https:\/\/doi.org\/10.1159\/000348736.","journal-title":"Ophthalmic Res"},{"key":"1779_CR72","unstructured":"Pakala RS, Brown KN, Preuss CV. Cholinergic Medications., in: Treasure Island (FL). 2024."},{"key":"1779_CR73","first-page":"130","volume":"5","author":"SM Drance","year":"1966","unstructured":"Drance SM. Comparison of Action of Cholinergic and anticholinesterase agents in Glaucoma. Invest Ophthalmol Vis Sci. 1966;5:130\u20135.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1779_CR74","unstructured":"Jackson J, Carr LW, Fisch BM, Malinovsky VE, Talley DK. Care of the patient with primary angle-closure glaucoma. Optom Clin Pract Guideline. 1994."},{"key":"1779_CR75","doi-asserted-by":"publisher","unstructured":"Aliancy J, Stamer WD, Wirostko B. A review of nitric oxide for the treatment of Glaucomatous Disease. Ophthalmol Ther. 2017;6. https:\/\/doi.org\/10.1007\/s40123-017-0094-6.","DOI":"10.1007\/s40123-017-0094-6"},{"key":"1779_CR76","doi-asserted-by":"publisher","unstructured":"Khoobehi B, Chiroli V, Ronchetti D, Miglietta D, Thompson H, Ongini E, Impagnatiello F. Enhanced oxygen saturation in optic nerve head of non-human primate eyes following the intravitreal injection of NCX 434, an innovative nitric oxide-donating glucocorticoid. J Ocul Pharmacol Ther. 2011;27. https:\/\/doi.org\/10.1089\/jop.2010.0150.","DOI":"10.1089\/jop.2010.0150"},{"key":"1779_CR77","doi-asserted-by":"publisher","unstructured":"Weinreb RN, Ong T, Sforzolini BS, Vittitow JL, Singh K, Kaufman PL, Ackerman S, Branch J, Cottingham A, Day D, Depenbusch M, El-Hazari S, Firozvi A, Jorizzo P, Ou R, Peace J, Rotberg M, Schenker H, Smith S, Tyson F, Zaman F, Madzharova L, Toshev R, Vassilveva P, Misiuk-Hoj\u0142o M, Koci\u0119cki J, Liehneova I, R\u016f\u017ei\u010dkov\u00e1 E. A randomised, controlled comparison of latanoprostene bunod and latanoprost 0.005% in the treatment of ocular hypertension and open angle glaucoma: the VOYAGER study. Br J Ophthalmol. 2015;99. https:\/\/doi.org\/10.1136\/bjophthalmol-2014-305908.","DOI":"10.1136\/bjophthalmol-2014-305908"},{"key":"1779_CR78","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.12-9483n","author":"GJ Chader","year":"2012","unstructured":"Chader GJ. Advances in glaucoma treatment and management: neurotrophic agents. Invest Ophthalmol Vis Sci. 2012. https:\/\/doi.org\/10.1167\/iovs.12-9483n.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1779_CR79","doi-asserted-by":"publisher","DOI":"10.4103\/2008-322X.183923","author":"A Doozandeh","year":"2016","unstructured":"Doozandeh A, Yazdani S. Neuroprotection in glaucoma. J Ophthalmic Vis Res. 2016. https:\/\/doi.org\/10.4103\/2008-322X.183923.","journal-title":"J Ophthalmic Vis Res"},{"key":"1779_CR80","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1997.01100150499009","author":"AH Neufeld","year":"1997","unstructured":"Neufeld AH, Hemandez R, Gonzalez M. Nitric oxide synthase in the human glaucomatous optic nerve head. Arch Ophthalmol. 1997. https:\/\/doi.org\/10.1001\/archopht.1997.01100150499009.","journal-title":"Arch Ophthalmol"},{"key":"1779_CR81","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006539.pub4","author":"DF Sena","year":"2017","unstructured":"Sena DF, Lindsley K. Neuroprotection for treatment of glaucoma in adults. Cochrane Database Syst Reviews. 2017. https:\/\/doi.org\/10.1002\/14651858.CD006539.pub4.","journal-title":"Cochrane Database Syst Reviews"},{"key":"1779_CR82","doi-asserted-by":"publisher","DOI":"10.1167\/tvst.7.3.1","author":"LE Downie","year":"2018","unstructured":"Downie LE, Vingrys AJ. Oral omega-3 supplementation lowers intraocular pressure in normotensive adults. Transl Vis Sci Technol. 2018. https:\/\/doi.org\/10.1167\/tvst.7.3.1.","journal-title":"Transl Vis Sci Technol"},{"key":"1779_CR83","unstructured":"Cybulska-Heinrich AK, Mozaffarieh M, Flammer J. Ginkgo biloba: An adjuvant therapy for progressive normal and high tension glaucoma, Mol Vis. 2012."},{"key":"1779_CR84","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.03-0567","author":"WA Hare","year":"2004","unstructured":"Hare WA, WoldeMussie E, Weinreb RN, Ton H, Ruiz G, Wijono M, Feldmann B, Zangwill L, Wheeler L. Efficacy and safety of memantine treatment for reduction of changes associated with experimental glaucoma in monkey, II: structural measures. Invest Ophthalmol Vis Sci. 2004. https:\/\/doi.org\/10.1167\/iovs.03-0567.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1779_CR85","doi-asserted-by":"publisher","DOI":"10.1097\/01.ijg.0000146372.74366.e4","author":"DS Greenfield","year":"2005","unstructured":"Greenfield DS, Girkin C, Kwon YH. Memantine and Progressive Glaucoma. J Glaucoma. 2005. https:\/\/doi.org\/10.1097\/01.ijg.0000146372.74366.e4.","journal-title":"J Glaucoma"},{"key":"1779_CR86","doi-asserted-by":"publisher","unstructured":"Tribble JR, Hui F, Quintero H, El Hajji S, Bell K, Di Polo A, Williams PA. Neuroprotection in glaucoma: mechanisms beyond intraocular pressure lowering. Mol Aspects Med. 2023;92. https:\/\/doi.org\/10.1016\/j.mam.2023.101193.","DOI":"10.1016\/j.mam.2023.101193"},{"key":"1779_CR87","doi-asserted-by":"publisher","first-page":"380","DOI":"10.4103\/ijo.IJO_1158_21","volume":"70","author":"CR Vishwaraj","year":"2022","unstructured":"Vishwaraj CR, Kavitha S, Venkatesh R, Shukla AG, Chandran P, Tripathi S. Indian J Ophthalmol. 2022;70:380\u20135. https:\/\/doi.org\/10.4103\/ijo.IJO_1158_21. Neuroprotection in glaucoma.","journal-title":"Indian J Ophthalmol"},{"key":"1779_CR88","doi-asserted-by":"publisher","unstructured":"Naik S, Pandey A, Lewis SA, Rao BSS, Mutalik S. Neuroprotection: a versatile approach to combat glaucoma. Eur J Pharmacol. 2020;881. https:\/\/doi.org\/10.1016\/j.ejphar.2020.173208.","DOI":"10.1016\/j.ejphar.2020.173208"},{"key":"1779_CR89","doi-asserted-by":"publisher","DOI":"10.4103\/0301-4738.73691","author":"K Singh","year":"2011","unstructured":"Singh K, Shrivastava A. Medical management of glaucoma: principles and practice. Indian J Ophthalmol. 2011. https:\/\/doi.org\/10.4103\/0301-4738.73691.","journal-title":"Indian J Ophthalmol"},{"key":"1779_CR90","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2004.12.035","author":"C.M.G Olthoff","year":"2005","unstructured":"Olthoff C.M.G., Schouten J.S.A.G., Van De Borne B.W., Webers C.A.B. Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension: an evidence-based review. Ophthalmology. 2005. https:\/\/doi.org\/10.1016\/j.ophtha.2004.12.035.","journal-title":"Ophthalmology"},{"key":"1779_CR91","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S118409","author":"A Farkouh","year":"2016","unstructured":"Farkouh A, Frigo P, Czejka M. Systemic side effects of eye drops: a pharmacokinetic perspective. Clin Ophthalmol. 2016. https:\/\/doi.org\/10.2147\/OPTH.S118409.","journal-title":"Clin Ophthalmol"},{"key":"1779_CR92","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.201900368","author":"R Moreddu","year":"2019","unstructured":"Moreddu R, Vigolo D, Yetisen AK. Contact Lens Technology: from fundamentals to applications. Adv Healthc Mater. 2019. https:\/\/doi.org\/10.1002\/adhm.201900368.","journal-title":"Adv Healthc Mater"},{"key":"1779_CR93","doi-asserted-by":"publisher","unstructured":"Peral A, Martinez-Aguila A, Pastrana C, Huete-Toral F, Carpena-Torres C, Carracedo G. Contact lenses as drug delivery system for glaucoma: a review. Appl Sci (Switzerland). 2020;10. https:\/\/doi.org\/10.3390\/app10155151.","DOI":"10.3390\/app10155151"},{"key":"1779_CR94","doi-asserted-by":"publisher","unstructured":"Rykowska I, Nowak I, Nowak R. Soft contact lenses as drug delivery systems: a review. Molecules. 2021;26. https:\/\/doi.org\/10.3390\/molecules26185577.","DOI":"10.3390\/molecules26185577"},{"key":"1779_CR95","doi-asserted-by":"publisher","DOI":"10.3109\/10717544.2016.1138342","author":"FA Maulvi","year":"2016","unstructured":"Maulvi FA, Soni TG, Shah DO. A review on therapeutic contact lenses for ocular drug delivery. Drug Deliv. 2016. https:\/\/doi.org\/10.3109\/10717544.2016.1138342.","journal-title":"Drug Deliv"},{"key":"1779_CR96","doi-asserted-by":"publisher","unstructured":"Musgrave CSA, Fang F. Contact lens materials: a materials science perspective. Materials. 2019;12. https:\/\/doi.org\/10.3390\/ma12020261.","DOI":"10.3390\/ma12020261"},{"key":"1779_CR97","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.jconrel.2018.05.020","volume":"281","author":"J Xu","year":"2018","unstructured":"Xu J, Xue Y, Hu G, Lin T, Gou J, Yin T, He H, Zhang Y, Tang X. A comprehensive review on contact lens for ophthalmic drug delivery. J Controlled Release. 2018;281:97\u2013118. https:\/\/doi.org\/10.1016\/j.jconrel.2018.05.020.","journal-title":"J Controlled Release"},{"key":"1779_CR98","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.clae.2016.11.005","volume":"40","author":"TS Bhamra","year":"2017","unstructured":"Bhamra TS, Tighe BJ. Mechanical properties of contact lenses: the contribution of measurement techniques and clinical feedback to 50 years of materials development. Contact Lens Anterior Eye. 2017;40:70\u201381. https:\/\/doi.org\/10.1016\/j.clae.2016.11.005.","journal-title":"Contact Lens Anterior Eye"},{"key":"1779_CR99","doi-asserted-by":"publisher","first-page":"3","DOI":"10.4103\/2229-5186.79342","volume":"2","author":"A Kumar","year":"2011","unstructured":"Kumar A, Jha G. Drug delivery through soft contact lenses: an introduction. Chronicles Young Scientists. 2011;2:3. https:\/\/doi.org\/10.4103\/2229-5186.79342.","journal-title":"Chronicles Young Scientists"},{"key":"1779_CR100","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1124\/jpet.119.256933","volume":"370","author":"V Gote","year":"2019","unstructured":"Gote V, Sikder S, Sicotte J, Pal D. Ocular drug delivery: present innovations and future challenges. J Pharmacol Exp Ther. 2019;370:602\u201324. https:\/\/doi.org\/10.1124\/jpet.119.256933.","journal-title":"J Pharmacol Exp Ther"},{"key":"1779_CR101","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.clae.2018.11.001","volume":"42","author":"M Zaki","year":"2019","unstructured":"Zaki M, Pardo J, Carracedo G. A review of international medical device regulations: contact lenses and lens care solutions. Contact Lens Anterior Eye. 2019;42:136\u201346. https:\/\/doi.org\/10.1016\/j.clae.2018.11.001.","journal-title":"Contact Lens Anterior Eye"},{"key":"1779_CR102","doi-asserted-by":"publisher","unstructured":"Franco P, de Marco I. Contact lenses as ophthalmic drug delivery systems: a review. Polym (Basel). 2021;13. https:\/\/doi.org\/10.3390\/polym13071102.","DOI":"10.3390\/polym13071102"},{"key":"1779_CR103","doi-asserted-by":"publisher","DOI":"10.1039\/c8bm00212f","author":"AR Desai","year":"2018","unstructured":"Desai AR, Maulvi FA, Pandya MM, Ranch KM, Vyas BA, Shah SA, Shah DO. Co-delivery of timolol and hyaluronic acid from semi-circular ring-implanted contact lenses for the treatment of glaucoma:: in vitro and in vivo evaluation. Biomater Sci. 2018. https:\/\/doi.org\/10.1039\/c8bm00212f.","journal-title":"Biomater Sci"},{"key":"1779_CR104","doi-asserted-by":"publisher","first-page":"45789","DOI":"10.1021\/ACSAMI.0C12667\/ASSET","volume":"12","author":"X Ding","year":"2020","unstructured":"Ding X, Ben-Shlomo G, Que L. Soft Contact Lens with embedded microtubes for sustained and self-adaptive drug delivery for Glaucoma treatment. ACS Appl Mater Interfaces. 2020;12:45789\u201395. https:\/\/doi.org\/10.1021\/ACSAMI.0C12667\/ASSET\/IMAGES\/LARGE\/AM0C12667_0008.JPEG.","journal-title":"ACS Appl Mater Interfaces"},{"key":"1779_CR105","doi-asserted-by":"publisher","DOI":"10.1021\/acsami.6b16509","author":"J Sun","year":"2017","unstructured":"Sun J, Lei Y, Dai Z, Liu X, Huang T, Wu J, Xu ZP, Sun X. Sustained release of Brimonidine from a New Composite Drug Delivery System for Treatment of Glaucoma. ACS Appl Mater Interfaces. 2017. https:\/\/doi.org\/10.1021\/acsami.6b16509.","journal-title":"ACS Appl Mater Interfaces"},{"key":"1779_CR106","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2016.02.012","author":"FA Maulvi","year":"2016","unstructured":"Maulvi FA, Lakdawala DH, Shaikh AA, Desai AR, Choksi HH, Vaidya RJ, Ranch KM, Koli AR, Vyas BA, Shah DO. In vitro and in vivo evaluation of novel implantation technology in hydrogel contact lenses for controlled drug delivery. J Controlled Release. 2016. https:\/\/doi.org\/10.1016\/j.jconrel.2016.02.012.","journal-title":"J Controlled Release"},{"issue":"6","key":"1779_CR107","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S43094-020-00128-9","volume":"6","author":"N Kumar","year":"2020","unstructured":"Kumar N, Aggarwal R, Chauhan MK. Extended levobunolol release from Eudragit nanoparticle-laden contact lenses for glaucoma therapy. Future J Pharm Sci 2020. 2020;6(6):1. https:\/\/doi.org\/10.1186\/S43094-020-00128-9.","journal-title":"Future J Pharm Sci 2020"},{"key":"1779_CR108","doi-asserted-by":"publisher","DOI":"10.1038\/natrevmats.2016.71","author":"J Li","year":"2016","unstructured":"Li J, Mooney DJ. Designing hydrogels for controlled drug delivery. Nat Rev Mater. 2016. https:\/\/doi.org\/10.1038\/natrevmats.2016.71.","journal-title":"Nat Rev Mater"},{"key":"1779_CR109","doi-asserted-by":"publisher","unstructured":"Lynch CR, Kondiah PPD, Choonara YE, du Toit LC, Ally N, Pillay V. Hydrogel Biomaterials for Application in Ocular Drug Delivery. Front Bioeng Biotechnol. 2020;8. https:\/\/doi.org\/10.3389\/FBIOE.2020.00228.","DOI":"10.3389\/FBIOE.2020.00228"},{"key":"1779_CR110","doi-asserted-by":"publisher","DOI":"10.1016\/j.carbpol.2016.02.080","author":"YH Cheng","year":"2016","unstructured":"Cheng YH, Tsai TH, Jhan YY, Chiu AWH, Tsai KL, Chien CS, Chiou SH, Liu CJL. Thermosensitive chitosan-based hydrogel as a topical ocular drug delivery system of latanoprost for glaucoma treatment. Carbohydr Polym. 2016. https:\/\/doi.org\/10.1016\/j.carbpol.2016.02.080.","journal-title":"Carbohydr Polym"},{"key":"1779_CR111","doi-asserted-by":"publisher","DOI":"10.1248\/cpb.c14-00451","author":"J Li","year":"2014","unstructured":"Li J, Liu H, Liu LL, Cai CN, Xin HX, Liu W. Design and evaluation of a brinzolamide drug-Resin in situ thermosensitive gelling system for sustained ophthalmic drug delivery. Chem Pharm Bull (Tokyo). 2014. https:\/\/doi.org\/10.1248\/cpb.c14-00451.","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"1779_CR112","doi-asserted-by":"publisher","unstructured":"Taka E, Karavasili C, Bouropoulos N, Moschakis T, Andreadis DD, Zacharis CK, Fatouros DG. Ocular co-delivery of Timolol and Brimonidine from a self-assembling peptide hydrogel for the treatment of Glaucoma: in Vitro and Ex vivo evaluation. Pharmaceuticals. 2020;13. https:\/\/doi.org\/10.3390\/ph13060126.","DOI":"10.3390\/ph13060126"},{"key":"1779_CR113","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222212368","author":"A Vaneev","year":"2021","unstructured":"Vaneev A, Tikhomirova V, Chesnokova N, Popova E, Beznos O, Kost O, Klyachko N. Nanotechnology for topical drug delivery to the anterior segment of the eye. Int J Mol Sci. 2021. https:\/\/doi.org\/10.3390\/ijms222212368.","journal-title":"Int J Mol Sci"},{"key":"1779_CR114","doi-asserted-by":"publisher","unstructured":"Fea AM, Novarese C, Caselgrandi P, Boscia G. Glaucoma treatment and hydrogel: current insights and state of the art. Gels. 2022;8. https:\/\/doi.org\/10.3390\/gels8080510.","DOI":"10.3390\/gels8080510"},{"key":"1779_CR115","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s12553-019-00381-w","volume":"10","author":"N Omerovi\u0107","year":"2020","unstructured":"Omerovi\u0107 N, Vrani\u0107 E. Application of nanoparticles in ocular drug delivery systems. Health Technol (Berl). 2020;10:61\u201378. https:\/\/doi.org\/10.1007\/s12553-019-00381-w.","journal-title":"Health Technol (Berl)"},{"key":"1779_CR116","doi-asserted-by":"publisher","unstructured":"bigdeli A, Makhmalzadeh BS, Feghhi M, SoleimaniBiatiani E. Cationic liposomes as promising vehicles for timolol\/brimonidine combination ocular delivery in glaucoma: formulation development and in vitro\/in vivo evaluation. Drug Deliv Transl Res. 2023;13. https:\/\/doi.org\/10.1007\/s13346-022-01266-8.","DOI":"10.1007\/s13346-022-01266-8"},{"key":"1779_CR117","doi-asserted-by":"publisher","unstructured":"Zembala J, Forma A, Zembala R, Januszewski J, Zembala P, Adamowicz D, Teresi\u0144ski G, Buszewicz G, Flieger J, Baj J. Technological advances in a therapy of primary Open-Angle Glaucoma: insights into current nanotechnologies. J Clin Med. 2023;12. https:\/\/doi.org\/10.3390\/jcm12185798.","DOI":"10.3390\/jcm12185798"},{"key":"1779_CR118","doi-asserted-by":"publisher","DOI":"10.22037\/ijpr.2017.2053","author":"MH Dehaghi","year":"2017","unstructured":"Dehaghi MH, Haeri A, Keshvari H, Abbasian Z, Dadashzadeh S. Dorzolamide loaded niosomal vesicles: comparison of passive and remote loading methods. Iran J Pharm Res. 2017. https:\/\/doi.org\/10.22037\/ijpr.2017.2053.","journal-title":"Iran J Pharm Res"},{"key":"1779_CR119","doi-asserted-by":"publisher","DOI":"10.2174\/1566523218666171129205626","author":"N Shrivastava","year":"2018","unstructured":"Shrivastava N, Khan S, Baboota S, Ali J. Fabrication and characterization of timolol maleate and Brinzolamide Loaded Nanostructured lipid Carrier System for Ocular Drug Delivery. Curr Drug Deliv. 2018. https:\/\/doi.org\/10.2174\/1566523218666171129205626.","journal-title":"Curr Drug Deliv"},{"key":"1779_CR120","doi-asserted-by":"publisher","DOI":"10.1208\/s12249-016-0669-x","author":"R Zhao","year":"2017","unstructured":"Zhao R, Li J, Wang J, Yin Z, Zhu Y, Liu W. Development of Timolol-Loaded Galactosylated Chitosan nanoparticles and evaluation of their potential for Ocular Drug Delivery. AAPS PharmSciTech. 2017. https:\/\/doi.org\/10.1208\/s12249-016-0669-x.","journal-title":"AAPS PharmSciTech"},{"key":"1779_CR121","doi-asserted-by":"publisher","first-page":"130498","DOI":"10.1016\/J.CEJ.2021.130498","volume":"425","author":"J Wang","year":"2021","unstructured":"Wang J, Li B, Huang D, Norat P, Grannonico M, Cooper RC, Gui Q, Nam Chow W, Liu X, Yang H. Nano-in-Nano dendrimer gel particles for efficient topical delivery of antiglaucoma drugs into the eye. Chem Eng J. 2021;425:130498. https:\/\/doi.org\/10.1016\/J.CEJ.2021.130498.","journal-title":"Chem Eng J"},{"key":"1779_CR122","doi-asserted-by":"publisher","first-page":"100847","DOI":"10.1016\/j.ajps.2023.100847","volume":"18","author":"H Yang","year":"2023","unstructured":"Yang H, Zhao M, Xing D, Zhang J, Fang T, Zhang F, Nie Z, Liu Y, Yang L, Li J, Wang D. Contact lens as an emerging platform for ophthalmic drug delivery: a systematic review. Asian J Pharm Sci. 2023;18:100847. https:\/\/doi.org\/10.1016\/j.ajps.2023.100847.","journal-title":"Asian J Pharm Sci"},{"key":"1779_CR123","doi-asserted-by":"publisher","first-page":"45789","DOI":"10.1021\/acsami.0c12667","volume":"12","author":"X Ding","year":"2020","unstructured":"Ding X, Ben-Shlomo G, Que L. Soft Contact Lens with embedded microtubes for sustained and self-adaptive drug delivery for Glaucoma treatment. ACS Appl Mater Interfaces. 2020;12:45789\u201395. https:\/\/doi.org\/10.1021\/acsami.0c12667.","journal-title":"ACS Appl Mater Interfaces"},{"key":"1779_CR124","doi-asserted-by":"publisher","first-page":"7990","DOI":"10.1021\/acsami.6b16509","volume":"9","author":"J Sun","year":"2017","unstructured":"Sun J, Lei Y, Dai Z, Liu X, Huang T, Wu J, Xu ZP, Sun X. Sustained release of Brimonidine from a New Composite Drug Delivery System for Treatment of Glaucoma. ACS Appl Mater Interfaces. 2017;9:7990\u20139. https:\/\/doi.org\/10.1021\/acsami.6b16509.","journal-title":"ACS Appl Mater Interfaces"},{"key":"1779_CR125","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s43094-020-00128-9","volume":"6","author":"N Kumar","year":"2020","unstructured":"Kumar N, Aggarwal R, Chauhan MK. Extended levobunolol release from Eudragit nanoparticle-laden contact lenses for glaucoma therapy. Futur J Pharm Sci. 2020;6:109. https:\/\/doi.org\/10.1186\/s43094-020-00128-9.","journal-title":"Futur J Pharm Sci"},{"key":"1779_CR126","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.carbpol.2016.02.080","volume":"144","author":"Y-H Cheng","year":"2016","unstructured":"Cheng Y-H, Tsai T-H, Jhan Y-Y, Chiu AW, Tsai K-L, Chien C-S, Chiou S-H, Liu CJ. Thermosensitive chitosan-based hydrogel as a topical ocular drug delivery system of latanoprost for glaucoma treatment. Carbohydr Polym. 2016;144:390\u20139. https:\/\/doi.org\/10.1016\/j.carbpol.2016.02.080.","journal-title":"Carbohydr Polym"},{"key":"1779_CR127","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1007\/s13346-022-01266-8","volume":"13","author":"A bigdeli","year":"2023","unstructured":"bigdeli A, Makhmalzadeh BS, Feghhi M, SoleimaniBiatiani E. Cationic liposomes as promising vehicles for timolol\/brimonidine combination ocular delivery in glaucoma: formulation development and in vitro\/in vivo evaluation. Drug Deliv Transl Res. 2023;13:1035\u201347. https:\/\/doi.org\/10.1007\/s13346-022-01266-8.","journal-title":"Drug Deliv Transl Res"},{"key":"1779_CR128","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1021\/nn4046024","volume":"8","author":"JV Natarajan","year":"2014","unstructured":"Natarajan JV, Darwitan A, Barathi VA, Ang M, Htoon HM, Boey F, Tam KC, Wong TT, Venkatraman SS. Sustained drug release in Nanomedicine: a long-acting nanocarrier-based formulation for Glaucoma. ACS Nano. 2014;8:419\u201329. https:\/\/doi.org\/10.1021\/nn4046024.","journal-title":"ACS Nano"},{"key":"1779_CR129","doi-asserted-by":"publisher","first-page":"8639","DOI":"10.1038\/s41598-017-09379-8","volume":"7","author":"MV Fedorchak","year":"2017","unstructured":"Fedorchak MV, Conner IP, Schuman JS, Cugini A, Little SR. Long term Glaucoma drug delivery using a topically retained Gel\/Microsphere Eye Drop. Sci Rep. 2017;7:8639. https:\/\/doi.org\/10.1038\/s41598-017-09379-8.","journal-title":"Sci Rep"},{"key":"1779_CR130","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1080\/02652040802095250","volume":"26","author":"JP Bertram","year":"2009","unstructured":"Bertram JP, Saluja SS, McKain J, Lavik EB. Sustained delivery of timolol maleate from poly(lactic-co-glycolic acid)\/poly(lactic acid) microspheres for over 3 months. J Microencapsul. 2009;26:18\u201326. https:\/\/doi.org\/10.1080\/02652040802095250.","journal-title":"J Microencapsul"},{"key":"1779_CR131","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.14-14651","author":"YC Kim","year":"2014","unstructured":"Kim YC, Edelhauser HF, Prausnitz MR. Targeted delivery of antiglaucoma drugs to the supraciliary space using microneedles. Invest Ophthalmol Vis Sci. 2014. https:\/\/doi.org\/10.1167\/iovs.14-14651.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1779_CR132","unstructured":"Einmahl S, Savoldelli M, D\u2019Hermies F, Tabatabay C, Gurny R, Behar-Cohen F. Evaluation of a novel biomaterial in the suprachoroidal space of the rabbit eye. Invest Ophthalmol Vis Sci. 2002;43:1533\u20131539."},{"key":"1779_CR133","doi-asserted-by":"publisher","DOI":"10.1021\/mp300716t","author":"P Tyagi","year":"2013","unstructured":"Tyagi P, Barros M, Stansbury JW, Kompella UB. Light-activated, in situ forming gel for sustained suprachoroidal delivery of bevacizumab. Mol Pharm. 2013. https:\/\/doi.org\/10.1021\/mp300716t.","journal-title":"Mol Pharm"},{"key":"1779_CR134","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.13-11747","author":"BC Gilger","year":"2013","unstructured":"Gilger BC, Abarca EM, Salmon JH, Patel S. Treatment of acute posterior uveitis in a porcine model by injection of triamcinolone acetonide into the suprachoroidal space using microneedles. Invest Ophthalmol Vis Sci. 2013. https:\/\/doi.org\/10.1167\/iovs.13-11747.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1779_CR135","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.17-23758","author":"JH Jung","year":"2018","unstructured":"Jung JH, Desit P, Prausnitz MR. Targeted drug delivery in the suprachoroidal space by swollen hydrogel pushing. Invest Ophthalmol Vis Sci. 2018. https:\/\/doi.org\/10.1167\/iovs.17-23758.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1779_CR136","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2016.02.041","author":"B Chiang","year":"2016","unstructured":"Chiang B, Kim YC, Doty AC, Grossniklaus HE, Schwendeman SP, Prausnitz MR. Sustained reduction of intraocular pressure by supraciliary delivery of brimonidine-loaded poly(lactic acid) microspheres for the treatment of glaucoma. J Controlled Release. 2016. https:\/\/doi.org\/10.1016\/j.jconrel.2016.02.041.","journal-title":"J Controlled Release"},{"key":"1779_CR137","unstructured":"Goldstein DA, Srivastava SK, Nguyen Q, Noronha G, Widmann M. A phase 1\/2 open-label, safety and tolerability study of triamcinolone acetonide administered to the suprachoroidal space in patients with non-infectious uveitis. Invest Ophthalmol Vis Sci. 2015;56:3557."},{"key":"1779_CR138","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2018.01.029","author":"RV Nair","year":"2018","unstructured":"Nair RV, Suresh SSA, Anoop KR, Nair SC. Sustained release timolol maleate loaded ocusert based on biopolymer composite. Int J Biol Macromol. 2018. https:\/\/doi.org\/10.1016\/j.ijbiomac.2018.01.029.","journal-title":"Int J Biol Macromol"},{"key":"1779_CR139","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2019.118662","author":"JR Franca","year":"2019","unstructured":"Franca JR, Foureaux G, Fuscaldi LL, Ribeiro TG, Castilho RO, Yoshida MI, Cardoso VN, Fernandes SOA, Cronemberger S, Nogueira JC, Ferreira AJ, Faraco AAG. Chitosan\/hydroxyethyl cellulose inserts for sustained-release of dorzolamide for glaucoma treatment: in vitro and in vivo evaluation. Int J Pharm. 2019. https:\/\/doi.org\/10.1016\/j.ijpharm.2019.118662.","journal-title":"Int J Pharm"},{"key":"1779_CR140","unstructured":"Veloso AAS, Zhu Q, Herrero-Vanrell R, Refojo MF. Ganciclovir-loaded polymer microspheres in rabbit eyes inoculated with human cytomegalovirus. Invest Ophthalmol Vis Sci. 1997;38:665\u201375."},{"key":"1779_CR141","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.201600780","author":"YS Pek","year":"2016","unstructured":"Pek YS, Wu H, Mohamed ST, Ying JY. Long-term Subconjunctival Delivery of Brimonidine tartrate for Glaucoma treatment using a Microspheres\/Carrier System. Adv Healthc Mater. 2016. https:\/\/doi.org\/10.1002\/adhm.201600780.","journal-title":"Adv Healthc Mater"},{"key":"1779_CR142","doi-asserted-by":"publisher","DOI":"10.1021\/nn4046024","author":"JV Natarajan","year":"2014","unstructured":"Natarajan JV, Darwitan A, Barathi VA, Ang M, Htoon HM, Boey F, Tam KC, Wong TT, Venkatraman SS. Sustained drug release in nanomedicine: a long-acting nanocarrier-based formulation for glaucoma. ACS Nano. 2014. https:\/\/doi.org\/10.1021\/nn4046024.","journal-title":"ACS Nano"},{"key":"1779_CR143","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2013.11.043","author":"V Mishra","year":"2014","unstructured":"Mishra V, Jain NK. Acetazolamide encapsulated dendritic nano-architectures for effective glaucoma management in rabbits. Int J Pharm. 2014. https:\/\/doi.org\/10.1016\/j.ijpharm.2013.11.043.","journal-title":"Int J Pharm"},{"key":"1779_CR144","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.201801047","author":"C Hu","year":"2018","unstructured":"Hu C, Sun J, Zhang Y, Chen J, Lei Y, Sun X, Deng Y. Local delivery and sustained-release of nitric Oxide Donor loaded in Mesoporous Silica Particles for Efficient Treatment of Primary Open-Angle Glaucoma. Adv Healthc Mater. 2018. https:\/\/doi.org\/10.1002\/adhm.201801047.","journal-title":"Adv Healthc Mater"},{"key":"1779_CR145","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.9b01137","author":"H Jeong","year":"2020","unstructured":"Jeong H, Park S, Park K, Kim M, Hong J. Sustained nitric oxide-providing small molecule and precise release behavior study for Glaucoma treatment. Mol Pharm. 2020. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.9b01137.","journal-title":"Mol Pharm"},{"key":"1779_CR146","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2011.11.085","author":"JY Lai","year":"2012","unstructured":"Lai JY, Hsieh AC. A gelatin-g-poly(N-isopropylacrylamide) biodegradable in situ gelling delivery system for the intracameral administration of pilocarpine. Biomaterials. 2012. https:\/\/doi.org\/10.1016\/j.biomaterials.2011.11.085.","journal-title":"Biomaterials"},{"key":"1779_CR147","doi-asserted-by":"publisher","DOI":"10.1038\/srep42344","author":"SF Chou","year":"2017","unstructured":"Chou SF, Luo LJ, Lai JY. In vivo pharmacological evaluations of pilocarpine-loaded antioxidant-functionalized biodegradable thermogels in glaucomatous rabbits. Sci Rep. 2017. https:\/\/doi.org\/10.1038\/srep42344.","journal-title":"Sci Rep"},{"key":"1779_CR148","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2017.11.008","author":"J Kim","year":"2018","unstructured":"Kim J, Kudisch M, da Silva NRK, Asada H, Aya-Shibuya E, Bloomer MM, Mudumba S, Bhisitkul RB, Desai TA. Long-term intraocular pressure reduction with intracameral polycaprolactone glaucoma devices that deliver a novel anti-glaucoma agent. J Controlled Release. 2018. https:\/\/doi.org\/10.1016\/j.jconrel.2017.11.008.","journal-title":"J Controlled Release"},{"key":"1779_CR149","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/J.ACTBIO.2020.04.055","volume":"111","author":"DD Nguyen","year":"2020","unstructured":"Nguyen DD, Luo LJ, Lai JY. Effects of shell thickness of hollow poly(lactic acid) nanoparticles on sustained drug delivery for pharmacological treatment of glaucoma. Acta Biomater. 2020;111:302\u201315. https:\/\/doi.org\/10.1016\/J.ACTBIO.2020.04.055.","journal-title":"Acta Biomater"},{"key":"1779_CR150","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0028720","author":"L Zou","year":"2011","unstructured":"Zou L, Nair A, Weng H, Tsai YT, Hu Z, Tang L. Intraocular pressure changes: an important determinant of the biocompatibility of intravitreous implants. PLoS ONE. 2011. https:\/\/doi.org\/10.1371\/journal.pone.0028720.","journal-title":"PLoS ONE"},{"key":"1779_CR151","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2017.02.037","author":"C Garc\u00eda-Caballero","year":"2017","unstructured":"Garc\u00eda-Caballero C, Prieto-Calvo E, Checa-Casalengua P, Garc\u00eda-Mart\u00edn E, Polo-Llorens V, Garc\u00eda-Feijoo J, Molina-Mart\u00ednez IT, Bravo-Osuna I. Herrero-Vanrell, six month delivery of GDNF from PLGA\/vitamin E biodegradable microspheres after intravitreal injection in rabbits. Eur J Pharm Sci. 2017. https:\/\/doi.org\/10.1016\/j.ejps.2017.02.037.","journal-title":"Eur J Pharm Sci"},{"key":"1779_CR152","unstructured":"Patel H, Dobrzykowski E, Ferrara G, Wilson B, Holmes C, Haley J. Ethylene-vinyl acetate (EVA) based technology to incorporate Axitinib and Timolol for long term sustained release. 2023."},{"key":"1779_CR153","doi-asserted-by":"publisher","DOI":"10.1016\/0039-9140(94)80110-X","author":"IB Butler","year":"1994","unstructured":"Butler IB, Schoonen MAA, Rickard DT. Removal of dissolved oxygen from water: a comparison of four common techniques. Talanta. 1994. https:\/\/doi.org\/10.1016\/0039-9140(94)80110-X.","journal-title":"Talanta"},{"key":"1779_CR154","doi-asserted-by":"publisher","DOI":"10.1208\/s12249-017-0712-6","author":"A Patil","year":"2017","unstructured":"Patil A, Singh S, Opere C, Dash A. Sustained-release delivery system of a slow hydrogen Sulfide Donor, GYY 4137, for potential application in Glaucoma. AAPS PharmSciTech. 2017. https:\/\/doi.org\/10.1208\/s12249-017-0712-6.","journal-title":"AAPS PharmSciTech"},{"key":"1779_CR155","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1975.01010020571003","author":"KL Macoul","year":"1975","unstructured":"Macoul KL, Pavan-Langston D. Pilocarpine Ocusert System for Sustained Control of Ocular Hypertension. Arch Ophthalmol. 1975. https:\/\/doi.org\/10.1001\/archopht.1975.01010020571003.","journal-title":"Arch Ophthalmol"},{"key":"1779_CR156","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-008-0875-7","author":"HJM Beckers","year":"2008","unstructured":"Beckers HJM, Schouten JSAG, Webers CAB, Valk R, Hendrikse F. Side effects of commonly used glaucoma medications: comparison of tolerability, chance of discontinuation, and patient satisfaction. Graefe\u2019s Archive Clin Experimental Ophthalmol. 2008. https:\/\/doi.org\/10.1007\/s00417-008-0875-7.","journal-title":"Graefe\u2019s Archive Clin Experimental Ophthalmol"},{"key":"1779_CR157","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-3768.1980.tb08319.x","author":"P Sihvola","year":"1980","unstructured":"Sihvola P, Puustj\u00e4rvi T. Pratical problems in the use of OCUSERT\u00ae-Pilocarpine delivery system. Acta Ophthalmol. 1980. https:\/\/doi.org\/10.1111\/j.1755-3768.1980.tb08319.x.","journal-title":"Acta Ophthalmol"},{"key":"1779_CR158","doi-asserted-by":"publisher","DOI":"10.18240\/ijo.2021.01.21","author":"NP Kesav","year":"2021","unstructured":"Kesav NP, Capitena Young CE, Ertel MK, Seibold LK, Kahook MY. Sustained-release drug delivery systems for the treatment of glaucoma. Int J Ophthalmol. 2021. https:\/\/doi.org\/10.18240\/ijo.2021.01.21.","journal-title":"Int J Ophthalmol"},{"key":"1779_CR159","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-020-00769-8","author":"M Shirley","year":"2020","unstructured":"Shirley M. Bimatoprost Implant: first approval. Drugs Aging. 2020. https:\/\/doi.org\/10.1007\/s40266-020-00769-8.","journal-title":"Drugs Aging"},{"key":"1779_CR160","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2016.11.020","author":"TR Walters","year":"2017","unstructured":"Walters TR, Lee SS, Goodkin ML, Whitcup SM, Robinson MR. Bimatoprost sustained-release implants for Glaucoma therapy: 6-Month results from a phase I\/II clinical trial. Am J Ophthalmol. 2017. https:\/\/doi.org\/10.1016\/j.ajo.2016.11.020.","journal-title":"Am J Ophthalmol"},{"key":"1779_CR161","doi-asserted-by":"publisher","unstructured":"Craven ER, Walters T, Christie WC, Day DG, Lewis RA, Goodkin ML, Chen M, Wangsadipura V, Robinson MR, Bejanian M, Aung T, Beck AD, Branch JD, Coote M, Crane CJ, Crichton A, Day S, Durcan FJ, Evans RM, Flynn WJ, Gagn\u00e9 S, Goldberg DF, Greiner JV, Jeppsen P, Jinapriya D, Johnson CS, Kurtz S, Mansberger SL, Martel JR, Perera SA, Rotberg MH, Saltzmann RM, Schenker HI, Tepedino ME, Yap-Veloso MIR, Uy HS. T.R. Walters, 24-Month Phase I\/II Clinical Trial of Bimatoprost Sustained-Release Implant (Bimatoprost SR) in Glaucoma Patients, Drugs. 2020. https:\/\/doi.org\/10.1007\/s40265-019-01248-0","DOI":"10.1007\/s40265-019-01248-0"},{"key":"1779_CR162","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2016.04.026","author":"JD Brandt","year":"2016","unstructured":"Brandt JD, Sall K, DuBiner H, Benza R, Alster Y, Walker G, Semba CP. Six-Month intraocular pressure reduction with a topical bimatoprost ocular insert: results of a phase II randomized controlled study. Ophthalmology. 2016. https:\/\/doi.org\/10.1016\/j.ophtha.2016.04.026.","journal-title":"Ophthalmology"},{"key":"1779_CR163","first-page":"481","volume":"55","author":"C Leahy","year":"2014","unstructured":"Leahy C, Gutner R, Varney W, Rulander J, Johnston S, Lai F, Crawford K, Ellis J. Ellis, continuous wear non-invasive device for sustained ocular drug delivery. Invest Ophthalmol Vis Sci. 2014;55:481.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1779_CR164","unstructured":"Mati Therapeutics. Mati therapeutics announces purchase of rights from novelion therapeutics inc. Business Wire, February 1, 2021. https:\/\/www.businesswire.com\/news\/home\/20210201005041\/en\/Mati-Therapeutics-Announces-Purchase-of-Rights-From-Novelion-Therapeutics-Inc"},{"key":"1779_CR165","unstructured":"Regeneron acquires UK-based biotech Oxular. EyeWire News. Accessed January 6, 2025. https:\/\/eyewire.news\/articles\/20121025-qlt_shows_positive_efficacy_trends_from_data_in_plug_combinations_in_phase_2_studies_for_glaucoma_using_latanoprost_punctal_plug_delivery_system\/"},{"key":"1779_CR166","first-page":"2110","volume":"58","author":"SL Mansberger","year":"2017","unstructured":"Mansberger SL, Conley J, Verhoeven RS, Blackwell K, Depenbusch M, Knox T, Walters TR, Ahmad I, Yerxa BR, Navratil T. Interim analysis of low dose ENV515 travoprost XR with 11 Month Duration followed by dose escalation and 28 day efficacy evaluation of high dose ENV515. Invest Ophthalmol Vis Sci. 2017;58:2110.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1779_CR167","unstructured":"Glaukos iDose TR demonstrates sustained iop reduction and favorable safety profile over 24 months in phase 2b study. EyeWire News. https:\/\/eyewire.news\/articles\/glaukos-idose-tr-demonstrates-sustained-iop-reduction-and-favorable-safety-profile-over-24-months-in-phase-2b-study\/"},{"key":"1779_CR168","first-page":"4266","volume":"61","author":"MH Goldstein","year":"2020","unstructured":"Goldstein MH, Goldberg D, Walters TR, Vantipalli S, Braun E, Metzinger JL. Evaluating Safety, Tolerability and Efficacy of an Intracameral Hydrogel-based Travoprost Implant in subjects with Glaucoma - phase 1 trial. Invest Ophthalmol Vis Sci. 2020;61:4266.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1779_CR169","unstructured":"Ocular therapeutix presents data demonstrating a reduction in IOP in patients treated with OTX-TIC. EyeWire News. https:\/\/eyewire.news\/articles\/ocular-therapeutix-presents-data-demonstrating-a-reduction-in-iop-in-patients-treated-with-otx-tic\/"}],"container-title":["Drug Delivery and Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-024-01779-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13346-024-01779-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-024-01779-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T12:51:38Z","timestamp":1745844698000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13346-024-01779-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,9]]},"references-count":169,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["1779"],"URL":"https:\/\/doi.org\/10.1007\/s13346-024-01779-4","relation":{},"ISSN":["2190-393X","2190-3948"],"issn-type":[{"value":"2190-393X","type":"print"},{"value":"2190-3948","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,9]]},"assertion":[{"value":"17 December 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All the authors agree to publish this article in Drug Delivery and Translational Research.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}